News & Updates

While I was finishing   my morning post on brincidofovir’s preliminary efficacy   in  immune  compromised patients with  adenoidal  infections, the announcement came that Thomas Eric Duncan had succumbed to Ebola Virus Disease in Dallas earlier this morning. I’ve been asked for some feedback because Mr. Duncan was reported to have received the Chimerix antiviral drug on Saturday afternoon. Adam Feuerstein at TheStreet just   expressed his disgust at the response of stock traders   within minutes of the announcement of Mr. Duncan’s death, by driving the stock price of Chimerix down 9% and that of rival Tekmira up 4.7%. Adam closes his post with the single word, “Gross.” One of his  commentators , however, wrote, “The market is reacting to news that brincidofovir failed in its first high profile test against Ebola, not cheering the death of an individual treated with it. Suggesting otherwise indicates the authors moral depravity.” Well, I’m now compelled to add my own learn